Occlusion Devices Market Report 2025

This occlusion devices market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The occlusion devices market size has grown strongly in recent years. It will grow from $3.83 billion in 2024 to $4.2 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to the demand for rising demand for minimal facilities of medical devices, increasing availability of diagnostic services, rising investment in healthcare infrastructure, high prevalence of chronic disorders, and increase in the spending on research and development.

The occlusion devices market size is expected to see strong growth in the next few years. It will grow to $6 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to high geriatric population, rise in the number of obese population, the increasing prevalence of heart related diseases, the increasing hypertension and rise in number of incidence of stroke. Major trends in the forecast period include transmuting technology and innovation, technological advancement, developing more precise and effective occlusion devices, product innovations, and integrating 3D printing.

The increasing demand for minimally invasive techniques is expected to drive growth in the occlusion devices market. Minimally invasive surgeries use small incisions or natural body openings to access and treat internal structures, organs, or tissues, minimizing trauma to the patient's body. These techniques offer medical, financial, and aesthetic benefits that attract both patients and healthcare providers, leading to rising demand across various medical disciplines. Occlusion devices, which block or close off blood vessels, ducts, or other pathways in the body, are crucial in minimally invasive procedures. They are commonly used in interventional cardiology, radiology, and other fields to treat conditions such as aneurysms, abnormal blood flow, or congenital heart defects. For example, in January 2023, Intuitive Surgical Inc., a US-based company specializing in minimally invasive care products, reported that approximately 1,875,000 surgical procedures were performed with its Vinci surgical systems in 2022, marking an 18% increase from about 1,594,000 procedures in 2021. This growth in minimally invasive techniques is driving the expansion of the occlusion devices market.

Major companies in the occlusion devices market are concentrating on developing innovative products, including aortic occlusion devices, to advance minimally invasive procedures and improve patient outcomes. Aortic occlusion devices are medical instruments designed to block or restrict blood flow in the aorta, often used in aortic surgeries or to manage certain aneurysms and emergencies. For example, in February 2022, Front Line Medical Technologies Inc., a US-based medical device company, introduced the COBRA-OS, an aortic occlusion device intended for critical scenarios, especially in resuscitative endovascular balloon occlusion of the aorta (REBOA) procedures. The COBRA-OS features a significantly smaller size of 4 F, which reduces procedure time and minimizes the risk of complications. It offers full, intermittent, or partial occlusion based on the patient's needs and includes a specially designed safety shoulder reservoir to help prevent aortic rupture during inflation. The COBRA-OS has been approved by Health Canada and cleared by the Food and Drug Administration (FDA) for use in the United States.

In November 2023, Amring Pharmaceuticals Inc., a specialty pharmaceutical company based in the United States, acquired Laminar Inc. for an undisclosed sum. This acquisition combines Nordic Pharma's pharmaceutical expertise with Visant’s FDA-cleared hyaluronic acid derivative, LACRIFILL, a canalicular occlusive device designed to temporarily block tear drainage by occluding the canalicular system. Visant Medical Inc., also a US-based company, manufactures medical devices aimed at treating dry eye.

Major companies operating in the occlusion devices market are Cardinal Health Inc., Johnson & Johnson, Abbott Laboratories, Medtronic PLC, Stryker Corporation, Boston Scientific Corporation, B. Braun Melsungen AG, Terumo Corporation, Edwards Lifesciences Corporation, Cook Group Incorporated, Merit Medical Systems Inc., Lepu Medical Technology (Beijing) Co. Ltd., MicroPort Scientific Corporation, Tokai Corporation, Penumbra Inc., Asahi Intecc Co. Ltd., Angiodynamics Inc., LeMaitre Vascular Inc., Biosensors International Group Ltd., Elixir Medical Corporation, Vascular Concepts Ltd., Acrostak Corporation.

North America was the largest region in the occlusion devices market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the occlusion devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the occlusion devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Occlusion devices are medical instruments designed to block or restrict the flow of blood or other fluids within the body. They are commonly used in procedures such as embolization to treat conditions such as aneurysms, vascular malformations, or to control bleeding. These devices include products such as coils, stents, and balloons and are essential in minimally invasive surgeries.

The main types of occlusion devices include occlusion removal devices, embolization devices, tubal occlusion devices, and support devices. Occlusion removal devices are designed to clear blockages in blood vessels or other bodily pathways. They find applications in various fields, including neurology, cardiology, peripheral vascular diseases, urology, oncology, and gynecology. The end users of these devices include hospitals, diagnostic centers, surgical centers, ambulatory care centers, research laboratories, and academic institutes.

The occlusion devices market research report is one of a series of new reports that provides occlusion devices market statistics, including occlusion devices industry global market size, regional shares, competitors with an occlusion devices market share, detailed occlusion devices market segments, market trends, and opportunities, and any further data you may need to thrive in the occlusion devices industry. This occlusion devices research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The occlusion devices market consists of sales of liquid embolic agents, flow diverters, balloon occlusion devices, emblemization coils, and endovascular stents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.